摘要:
The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to EGFR on tumor cells that overexpress EGFR, and on tumor cells that express the truncated version of the EGFR receptor, de2-7 EGF. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.
摘要:
The invention relates to specific binding members, particularly antibodies and active fragments thereof, which recognize an aberrant post-translationally modified, particularly an aberrant glycosylated form of the EGFR. The binding members, particularly antibodies and fragments thereof, of the invention do not bind to EGFR on normal cells in the absence of amplification of the wild-type gene and are capable of binding the de2-7 EGFR at an epitope which is distinct from the junctional peptide. Antibodies of this type are exemplified by the novel antibody 806 whose VH and VL sequences are illustrated as SEQ ID NOs: 2 and 4 and chimeric antibodies thereof as exemplified by ch806.
摘要:
The invention relates to specific binding members, particularly antibodies and active fragments thereof, which recognize an aberrant post-translationally modified, particularly an aberrant glycosylated form of the EGFR. The binding members, particularly antibodies and fragments thereof, of the invention do not bind to EGFR on normal cells in the absence of amplification of the wild-type gene and are capable of binding the de2-7 EGFR at an epitope which is distinct from the junctional peptide. Antibodies of this type are exemplified by the novel antibody 806 whose VH and VL sequences are illustrated as SEQ ID NOs: 2 and 4 and chimeric antibodies thereof as exemplified by ch806.
摘要翻译:本发明涉及特异性结合成员,特别是抗体及其活性片段,其识别异常翻译后修饰,特别是EGFR的异常糖基化形式。 本发明的结合成员,特别是抗体及其片段在正常细胞上不与野生型基因扩增结合,并且能够以不同于 连接肽。 这种抗体的例子是其VH和VL序列如SEQ ID NO:2和4以及其嵌合抗体如ch806所示的新抗体806。
摘要:
In accordance with aspects of the disclosure, a system and methods are provided for managing business objects in memory. The system and methods may be provided for defining a context of one or more input parameters of data used to determine one or more properties of one or more business objects, defining one or more rules associated with the one or more properties of each business object, and generating a metadata model for each business object based on the context of the one or more input parameters of each business object and the one or more rules associated with the one or more properties of each business object.
摘要:
Methods and systems consistent with the present invention provide a data processing system having a business object model reflecting the data used during a business transaction. Consistent interfaces are generated from the business object model. These interfaces are suitable for use across industries, across businesses, and across different departments within a business during a business transaction.
摘要:
Methods and systems consistent with the present invention provide a data processing system having a business object model reflecting the data used during a business transaction. Consistent interfaces are generated from the business object model. These interfaces are suitable for use across industries, across businesses, and across different departments within a business during a business transaction.
摘要:
According to one general aspect, a method of retrieving data entities from a backend data device may include maintaining a data model of data entities employed by a user interface. The data model may include a hierarchical relationship between a leading data entity and at least one child data entity. The method may also include authorizing, with an authorization device, when retrieving the leading data entity. The method may include instructing the authorization device that data retrievals of subsequent data entities are to be authorized based upon the authorization of the leading data entity. The method may also include retrieving at least one child data entity of the leading data entity without providing additional authorization credentials.
摘要:
The invention relates to the discovery of cancer antigens associated with ovarian cancer. In further aspects, the invention relates to methods, compositions and kits for the diagnosis and treatment of cancer, particularly ovarian and pancreatic cancers.
摘要:
New bifunctional chelation complexes are described. These are based on the structure of the so-called “TAME-HexA” molecule. The compounds are especially useful for forming chelation complexes with metal ions, including radioisotopes.
摘要:
The invention relates to peptides which bind to MHC Class I and to MHC Class II molecules. These peptides are useful in different therapeutic and diagnostic contexts.